Skip to main content
. 2020 May 21;20(2):802–809. doi: 10.3892/etm.2020.8782

Figure 4.

Figure 4

TRIM31 regulates TMZ resistance via the PI3K/Akt signaling pathway. (A) Protein expression levels of p-AKT and AKT in A172 and U251 cells transfected with the indicated plasmids and treated with TMZ. (B) Protein expression levels of p-AKT and AKT in U251 cells transfected with siTRIM31 and siNC and treated with TMZ. (C) Cell viability of A172 cells transfected with the TRIM31 and control plasmids and treated with the PI3K inhibitor, LY294002, and TMZ. (D) Protein expression levels of p-AKT and AKT in A172 cells transfected with the TRIM31 and control plasmids and treated with the PI3K inhibitor, LY294002, and TMZ. *P<0.05, ***P<0.001. Data are presented as the mean ± standard deviation of three independent experiments. TMZ, temozolomide; si, small interfering; NC, negative control; TRIM31, tripartite motif-containing 31; p, phosphorylated.